Technology Commercialization Office

Showing 37 result(s) for "Therapeutics"



The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.

A treatment for spinal muscular atrophy.

A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia.

Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.

A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.

Ohio State University researchers have discovered novel subset of human CD34 (+) hematopoietic precursor cells and generated a method of isolating them.

A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

Medical device for controlling seizures.

A novel method to increase the effectiveness and practicality of the cancer treatment drug Flavopiridol.